Acquisitions and Related Arrangements - Kinnate Acquisition (Details) - USD ($) $ / shares in Units, $ in Thousands		1 Months Ended	3 Months Ended	12 Months Ended
	Sep. 17, 2025	Apr. 30, 2024	Sep. 30, 2025	Dec. 31, 2025	Dec. 31, 2024	Apr. 03, 2024
Asset Acquisition
Total purchase consideration	$ 105,349
Exarafenib milestone contingent consideration				$ 3,600	$ 3,214
CVR Agreement | Kinnate CVR holders
Asset Acquisition
Exarafenib milestone contingent consideration				3,600	$ 3,200
Kinnate
Asset Acquisition
Asset acquisition, share price (in dollars per share)						$ 2.5879
Total purchase consideration		$ 126,400
Reduction to gain on acquisition			$ 1,700
Asset acquisition reduction to prepaid expenses and other current assets			300
Asset acquisition reduction to other assets long term			1,000
Asset acquisition reduction to general and administrative expenses			$ 400
Kinnate | Kinnate CVR holders
Asset Acquisition
Contingent consideration				600
Contingent consideration liability, current				$ 600
Kinnate | CVR Agreement | Kinnate CVR holders
Asset Acquisition
Percentage share from potential milestone		100.00%
Cash received from milestone payments		$ 30,500